PromarkerD launched into the US at major diabetes conference
Filed with ASX · · 3 pages · English
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- Supplementary Prospectus
- A landmark in non-invasive Esophageal Cancer diagnosis
- $12 million capital raise completed with oversubscribed SPP
- PromarkerEndo latest results presented at world congress
- Chinese patent granted for OxiDx technology
Later from Proteomics International Laboratories
- First patent for endometriosis blood test - granted in Japan
- Funding boost for precision diagnostics Proteomics Facility
- AMA grants reimbursement code for Next-Gen PromarkerD test
- OxiDx test detects muscle damage in thoroughbred racehorses
- Preliminary Final Report
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories